Bryan Luce

Summary

Affiliation: United BioSource Corporation
Country: USA

Publications

  1. doi request reprint Health technology assessment in the United States
    Bryan Luce
    United BioSource Corporation, Bethesda, Maryland 20814, USA
    Int J Technol Assess Health Care 25:33-41. 2009
  2. pmc EBM, HTA, and CER: clearing the confusion
    Bryan R Luce
    United BioSource Corporation, Bethesda, MD, USA
    Milbank Q 88:256-76. 2010
  3. doi request reprint Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States
    Bryan R Luce
    United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    Vaccine 26:2841-8. 2008
  4. ncbi request reprint Can managed care organizations partner with manufacturers for comparative effectiveness research?
    Bryan R Luce
    United BioSource Corporation, 7101 Wisconsin Ave, Ste 600, Bethesda, MD 20814, USA
    Am J Manag Care 14:149-56. 2008
  5. ncbi request reprint What will it take to make cost-effectiveness analysis acceptable in the United States?
    Bryan R Luce
    MEDTAP Institute at United BioSource Corporation UBC, Bethesda, Maryland 20814, USA
    Med Care 43:44-8. 2005
  6. doi request reprint Value of biologic therapy: a forecasting model in three disease areas
    L Clark Paramore
    Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Lexington, MA 02420, USA
    Curr Med Res Opin 26:41-51. 2010
  7. ncbi request reprint The return on investment in health care: from 1980 to 2000
    Bryan R Luce
    United BioSource Corporation, Bethesda, MD 20814, USA
    Value Health 9:146-56. 2006
  8. ncbi request reprint Economic burden of heart failure: a summary of recent literature
    Won Chan Lee
    Abt Associates Inc HERQuLES, Bethesda, MD, USA
    Heart Lung 33:362-71. 2004
  9. ncbi request reprint The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis
    Ya Chen Tina Shih
    MEDTAP International, Inc, Bethesda, Maryland 20814, USA
    Clin Ther 24:701-16. 2002
  10. ncbi request reprint Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting
    Kevin B Weiss
    Northwestern University Medical School, Chicago, Illinois, USA
    J Asthma 42:769-76. 2005

Detail Information

Publications14

  1. doi request reprint Health technology assessment in the United States
    Bryan Luce
    United BioSource Corporation, Bethesda, Maryland 20814, USA
    Int J Technol Assess Health Care 25:33-41. 2009
    ..To describe and explore the reasons for the current health technology assessment (HTA) landscape in the United States...
  2. pmc EBM, HTA, and CER: clearing the confusion
    Bryan R Luce
    United BioSource Corporation, Bethesda, MD, USA
    Milbank Q 88:256-76. 2010
    ..The objective of this article is to clarify their definitions and the relationships among key terms and concepts...
  3. doi request reprint Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States
    Bryan R Luce
    United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    Vaccine 26:2841-8. 2008
    ....
  4. ncbi request reprint Can managed care organizations partner with manufacturers for comparative effectiveness research?
    Bryan R Luce
    United BioSource Corporation, 7101 Wisconsin Ave, Ste 600, Bethesda, MD 20814, USA
    Am J Manag Care 14:149-56. 2008
    ..To describe 2 published pragmatic or practical clinical trials (PCTs) as case studies illustrating successful partnerships between managed care organizations (MCOs) and pharmaceutical manufacturers...
  5. ncbi request reprint What will it take to make cost-effectiveness analysis acceptable in the United States?
    Bryan R Luce
    MEDTAP Institute at United BioSource Corporation UBC, Bethesda, Maryland 20814, USA
    Med Care 43:44-8. 2005
    ..It discounts many of the conventional arguments regarding the real obstacles to using CEA and suggests steps needed to make CEA more acceptable to US healthcare decision-makers...
  6. doi request reprint Value of biologic therapy: a forecasting model in three disease areas
    L Clark Paramore
    Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Lexington, MA 02420, USA
    Curr Med Res Opin 26:41-51. 2010
    ..Forecast the return on investment (ROI) for advances in biologic therapies in years 2015 and 2030, based upon impact on disease prevalence, morbidity, and mortality for asthma, diabetes, and colorectal cancer...
  7. ncbi request reprint The return on investment in health care: from 1980 to 2000
    Bryan R Luce
    United BioSource Corporation, Bethesda, MD 20814, USA
    Value Health 9:146-56. 2006
    ..To estimate the return on US investment (ROI) in overall health as well as four specific conditions...
  8. ncbi request reprint Economic burden of heart failure: a summary of recent literature
    Won Chan Lee
    Abt Associates Inc HERQuLES, Bethesda, MD, USA
    Heart Lung 33:362-71. 2004
    ..Methods A key-word search of literature indexes for relevant citations identified 54 articles that were then summarized for findings on HF economics...
  9. ncbi request reprint The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis
    Ya Chen Tina Shih
    MEDTAP International, Inc, Bethesda, Maryland 20814, USA
    Clin Ther 24:701-16. 2002
    ..The US Food and Drug Administration (FDA) recently held a meeting to determine whether the status of second-generation antihistamines (SGAs) should be switched from prescription (Rx) to over-the-counter (OTC) status...
  10. ncbi request reprint Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting
    Kevin B Weiss
    Northwestern University Medical School, Chicago, Illinois, USA
    J Asthma 42:769-76. 2005
    ..Patients treated with budesonide were significantly more satisfied and compliant with their inhaled corticosteroid regimen compared with patients treated with triamcinolone acetonide...
  11. ncbi request reprint Evidence based? Caveat emptor!
    Earl P Steinberg
    Resolution Health Inc, San Jose, California, USA
    Health Aff (Millwood) 24:80-92. 2005
    ....
  12. doi request reprint Key principles for the improved conduct of health technology assessments for resource allocation decisions
    Michael F Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 24:244-58; discussion 362-8. 2008
    ..The principles are organized into four sections: (i) "Structure" of HTA programs; (ii) "Methods" of HTA; (iii) "Processes for Conduct" of HTA; and (iv) "Use of HTAs in Decision Making."..
  13. ncbi request reprint Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settings
    Kevin B Weiss
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Clin Ther 26:102-14. 2004
    ..However, effectiveness and cost-effectiveness comparisons of available inhaled corticosteroids in real-life clinical settings are lacking...
  14. ncbi request reprint Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies
    Milton C Weinstein
    Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Value Health 6:9-17. 2003
    ..This report describes the consensus of a task force convened to provide modelers with guidelines for conducting and reporting modeling studies...